Sigbjørn Berentsen Selected Research

Sigbjørn Berentsen Research Topics

33	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 12/2023 - 04/2004
17	Hemolysis 05/2023 - 06/2014
6	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 12/2023 - 03/2014
5	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 11/2019 - 01/2015
4	Fatigue 01/2023 - 01/2021
3	Infections 01/2023 - 05/2012
3	Anemia 01/2023 - 11/2009
3	Hemolytic Anemia 11/2021 - 01/2019
2	Neoplasms (Cancer) 06/2015 - 05/2012
2	B-Cell Lymphoma (Lymphoma, B Cell) 03/2014 - 09/2007
1	Neutropenia 01/2023
1	Hypertension (High Blood Pressure) 01/2022
1	Rhinitis 01/2022
1	Raynaud Disease (Raynaud's Disease) 01/2022
1	Headache (Headaches) 01/2022
1	Long Term Adverse Effects 01/2020
1	Multiple Myeloma 01/2019
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2018
1	Acute-Phase Reaction 05/2017
1	Lymphoma (Lymphomas) 03/2014
1	Hemochromatosis (Bronze Diabetes) 01/2014
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 09/2012
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 03/2009
1	Cytopenia 12/2007
1	Thrombosis (Thrombus) 09/2002
1	Pulmonary Embolism 09/2002

16	Complement System Proteins (Complement)IBA 05/2023 - 06/2014
9	AgglutininsIBA 11/2021 - 03/2009
8	Rituximab (Mabthera)FDA Link 01/2020 - 04/2004
5	sutimlimabIBA 05/2023 - 01/2021
5	Hemoglobins (Hemoglobin)IBA 01/2023 - 01/2021
5	cold agglutininsIBA 01/2020 - 09/2007
4	AutoantibodiesIBA 12/2023 - 09/2007
4	Monoclonal AntibodiesIBA 01/2023 - 06/2014
3	Bendamustine Hydrochloride FDA Link 01/2023 - 01/2017
2	Immunoglobulin M (IgM)IBA 12/2023 - 01/2020
2	BilirubinIBA 01/2023 - 01/2021
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023 - 11/2009
2	Immunoglobulin G (IgG)IBA 01/2023 - 01/2022
2	Complement Inactivating AgentsIBA 01/2023 - 10/2022
2	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 01/2016
2	fludarabineIBA 01/2020 - 10/2010
2	Surface Antigens (Surface Antigen)IBA 05/2017 - 09/2007
1	Complement Receptors (Complement Receptor)IBA 12/2023
1	I-antigenIBA 12/2023
1	Complement C1s (C1 Esterase)IBA 01/2023
1	ibrutinibIBA 11/2021
1	daratumumabIBA 10/2020
1	AntibodiesIBA 01/2020
1	AntigensIBA 01/2020
1	Blood Proteins (Serum Proteins)IBA 01/2019
1	Immunoglobulin A (IgA)IBA 01/2019
1	eculizumab FDA Link 05/2017
1	TNT003IBA 06/2014
1	Blood Group Antigens (Blood Groups)IBA 03/2014
1	Ferritins (Ferritin)IBA 01/2014
1	IronIBA 09/2012

20	Therapeutics 01/2023 - 09/2002
2	Drug Therapy (Chemotherapy) 01/2018 - 11/2009
1	Radiotherapy 01/2018
1	Blood Component Removal (Apheresis) 01/2014
1	Chelation Therapy (Therapy, Chelation) 09/2012
1	Aftercare (After-Treatment) 04/2004
1	Thrombolytic Therapy 09/2002
1	Catheters 09/2002